Observational studyNeurocritical care2026
Early Positive Fluid Balance as a Clinical Marker of Systemic Capillary Leak and Clazosentan Intolerance After Aneurysmal Subarachnoid Hemorrhage.
Observational study in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClazosentan, a selective endothelin A receptor antagonist, mitigates cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH). Although it reduces vasospasm-related events, it is also associated with adverse events (AEs) related to fluid retention, which are hypothesized to stem from systemic capillary leaks. These AEs often necessitate early discontinuation of therapy. This study aimed to identify early clinical markers of clazosentan intolerance, specifically focusing on fluid balance.
methodsThis sub-analysis utilized data from the RECOVER registry, focusing on 208 patients diagnosed with aSAH who received clazosentan. Postoperative fluid status was quantified by calculating the mean daily fluid balance during postoperative days (POD) 1-3. The primary endpoint was discontinuation of clazosentan because of AEs. To identify independent predictors, a multivariable logistic regression analysis was conducted. A favorable outcome was defined as a modified Rankin Scale score of 0-2 at discharge.
resultsA total of 31 (14.9%) patients discontinued clazosentan on POD 6 [interquartile range (IQR), 3-10]. Discontinuation was most frequently attributed to worsening respiratory status (13/31, 41.9%), consistent with fluid overload. During POD 1-3, fluid intake was comparable between groups, whereas urine output was lower in those who discontinued treatment, yielding an early positive balance. Spline analysis showed a sharp risk rise beyond + 750 mL/day; dichotomization at this threshold confirmed an independent association with discontinuation [≥ +750 mL/day: adjusted odds ratio (OR), 3.41; 95% confidence interval (CI), 1.29-8.92; p = 0.012). Discontinuation was associated with lower odds of a favorable outcome (46.7% vs. 68.6%; adjusted OR, 0.40; 95% CI 0.18-0.88; p = 0.023).
conclusionsEarly positive fluid balance was a strong independent predictor of clazosentan discontinuation and was associated with poor functional outcomes. Early postoperative fluid balance may serve as a practical bedside marker of clazosentan intolerance and fluid-retentive physiological response, potentially involving increased vascular permeability. Goal-directed fluid management targeting euvolemia during the first 72 h may help optimize tolerability and enhance the therapeutic efficacy of clazosentan.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.